Table 1. Basic characteristics of the population. Univariate comparison.
| Factors | Cancer, n=149 (5%) | No cancer, n=2898 (95%) | P-value |
|---|---|---|---|
| Age (years) | 64 (59–72) | 59 (54–67) | <0.0001a |
| BMI (kg m−2) | 31 (27–36) | 28 (25–32) | <0.0001a |
| Diabetes | |||
| Yes | 25 (17%, 11–24%) | 158 (5%, 5–6%) | <0.0001b |
| No | 124 (83%, 76–89%) | 2740 (95%, 94–95%) | |
| Hypertension | |||
| Yes | 56 (38%, 30–46%) | 741 (26%, 24–27%) | 0.001b |
| No | 93 (62%, 54–70%) | 2157 (74%, 73–76%) | |
| HRT duration (years) | 9 (4–20) | 5 (2–10) | 0.243a |
| Breast cancer | |||
| Yes | 16 (11%, 6–17%) | 178 (6%, 5–7%) | 0.025b |
| No | 133 (89%, 83–94%) | 2720 (94%, 93–95%) | |
| Tamoxifen use (years) | 4.5 (2–8) | 3 (2–5) | 0.091a |
| Amount of bleeding* | |||
| Spotting | 39 (27%, 20–35%) | 611 (21%, 20–23%) | |
| Light | 80 (55%, 46–63%) | 1620 (57%, 55–59%) | 0.289b |
| Heavy | 27 (18%, 13–26%) | 614 (22%, 20–23%) | |
| Frequency of bleeding* | |||
| Single | 36 (24%, 18–32%) | 1541 (53%, 52–55%) | <0.0001b |
| Recurrent | 112 (76%, 68–82%) | 1345 (47%, 45–48%) | |
| Endometrial thickness (mm) | 14.9 (11.0–21.0) | 4.6 (3.0–7.8) | <0.0001a |
Abbreviations: BMI=body mass index; HRT=hormone replacement therapy.
Values are median (inter-quartile range), number (percent, 95% CI of percent).
a
Two-sample Wilcoxon rank sum test (Mann–Whitney test).
b
χ2-Test.
*Percentages worked on less numbers from the overall due to missing values.